Aug 2026· Acta Pharmacologica Sinica· Vol 47, pp. 2791 - 2819· 0 citations· 277 references
Medicine
TL;DR
Key approaches targeting DNA repair deficiency, immune regulation, oncogenic signaling pathways, and antigen-directed therapies are highlighted, and their clinical development and application are discussed.
This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...
Zi-Xun Wang, Xi-Yu Liu, Yu-Xiao Wu et al.· Journal of Hematology & Onco...· 0 citations
The immunological characteristics of TNBC, the current status of ICI-based therapy, and the underlying mechanisms of resistance are reviewed, which summarizes the biological rationale for combining RT with ICIs in the treatment of TNBC and explores the impact of different RT dose-fractionation regimens, treatment seque...
Lu Wang, Xin Bai, Fan Wang et al.· Frontiers in Immunology· 0 citations
INTRODUCTION
Triple-negative breast cancers (TNBCs) are a type of breast cancer (BC) characterized by the absence of ER, PR, and HER2 expression. They account for 10-15% of invasive BC cases and are known for being aggressive and highly metastatic. TNBC patients face limited effective treatment options due to the inher...
Parth Malik, V. Patel, R. Maitra et al.· Current Drug Targets· 0 citations
The evolving biological basis of therapeutic resistance is examined and how emerging treatment strategies may be integrated into biologically informed clinical development is discussed to improve patient selection, guide therapeutic sequencing, and increase the durability of treatment benefit in extensive-stage SCLC.
Jun Kim, Seounghun Kang· Pharmaceuticals· 0 citations
Breast cancer is a leading cause of cancer -related morbidity and mortality, characterized by significant biological and molecular heterogeneity. Molecular subtypes —including luminal A, luminal B, HER2 - enriched, and triple -negative—inform prognosis and guide prec ision therapies. Despite advances with endocrine age...
Triple-negative breast cancer is an aggressive, biologically heterogeneous subtype with limited targeted therapies. Immunotherapy improves outcomes in selected patients, but durable benefit is limited by inter- and intratumoral heterogeneity, imperfect biomarkers, and primary or acquired resistance. This review integra...
Shun-Hao Peng, Meng-Yao Qin, G. Song et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
